Last reviewed · How we verify
NCT06815783: CONDUCT USe
Novel Approach to Conduction System Pacing With Use of Ultrasound
NA trial testing Ultrasound guidance in Conduction Block, Atrioventricular in 152 participants. Participants enrolled and being followed up; not accepting new ones.
28 February 2028
Quick facts
| Lead sponsor | Habib Khan |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 152 |
| Start date | 10 April 2025 |
| Primary completion | 28 February 2028 |
| Estimated completion | 28 February 2029 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Ultrasound guidance
- Fluoroscopy guided
Conditions studied
- Conduction Block, Atrioventricular — all drugs for Conduction Block, Atrioventricular →
- Bundle-Branch Block — all drugs for Bundle-Branch Block →
Sponsor
Habib Khan
Who can join
18 and older, any sex, with Conduction Block, Atrioventricular or Bundle-Branch Block. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Each year, over one million pacemakers are implanted globally using x-rays. Recent developments have been aimed at determining which area of the heart is the best option for lead placement. An area in the septum separating the verticals called the left bundle branch area (LBBA) has previously been identified as a safe and effective area for lead placement. However, as the LBBA location is in the center of the heart, it is impossible to see the entire extent using X-ray. Current practice requires x-ray guidance to estimate the location and pacing parameters to confirm proximity. Implanting in LBBA takes longer procedure times and higher exposure to X-ray radiation for both patients and hospital staff. Over time, radiation poses an increased risk of cancer and other medical issues. This study will determine if using ultrasound can improve pacemaker lead implantation to the LBBA. Benefits to patients may include fewer attempts and more accuracy in lead deployment, thereby reducing risks and providing improved outcomes. Benefits to healthcare delivery may include reduction in total procedure time, thereby allowing more cases per day to reduce waitlist, and reduced X-ray exposure to staff thereby reducing cumulative effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06815783
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ultrasound guidance
Trials testing the same drug.
- NCT06065943 — Ultrasound-guided In-plane Puncture of the Femoral Artery · NA · completed
- NCT04900324 — Intramuscular Injections of Botulinum Toxin in Lateral Pterygoid Muscle in the Treatment of Temporomandibular Dysfunctio · NA · terminated
- NCT03727581 — Ultrasound for Guidewire Detection · completed
Other recruiting trials for Conduction Block, Atrioventricular
Currently open trials in the same condition.
- NCT05910866 — LEft Bundle branchArea Pacing to Avoid Pacing-induced CARdiomyopathy · NA · recruiting
Other Habib Khan trials
Trials by the same sponsor.
- NCT06299514 — RAFT - Pace &Ablate · NA · recruiting
- NCT05428787 — Resynchronization in Patients With HF in AF Trial Undergoing Pace & AVNA Strategy With LBBAP Compared With BiV Pacing · NA · active not recruiting
- NCT04858698 — Reduction Or Elimination Of Radiation During Implantation of Cardiac Devices Using Ultrasound · NA · unknown
- NCT04842227 — Blocks Alternative to Sedation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06815783 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Habib Khan
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06815783.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing